Get the Stockscreener App
569.50
1.83%
12.69
Regeneron Pharmaceuticals Inc stock is traded at $569.50, with a volume of 1.15M.
It is up +1.83% in the last 24 hours and down -19.86% over the past month.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$556.81
Open:
$538
24h Volume:
1.15M
Relative Volume:
1.26
Market Cap:
$58.78B
Revenue:
$14.20B
Net Income/Loss:
$4.41B
P/E Ratio:
14.88
EPS:
38.28
Net Cash Flow:
$3.54B
1W Performance:
-9.36%
1M Performance:
-19.86%
6M Performance:
-43.98%
1Y Performance:
-39.93%
1-Day Range:
$525.99
$575.47
1-Week Range:
$525.99
$628.00
52-Week Range:
$525.99
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
567.21 | 58.78B | 14.20B | 4.41B | 3.54B | 38.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.07 | 118.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
ARGX
Argen X Se Adr
|
560.94 | 32.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.62 | 28.16B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
206.03 | 22.43B | 3.81B | -644.79M | -669.77M | -6.24 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Is Regeneron Pharmaceuticals Gaining or Losing Market Support? - Benzinga
Morgan Stanley Adjusts PT on Regeneron Pharmaceuticals to $1,081 From $1,150, Keeps Overweight Rating - MarketScreener
Diabetic Retinopathy Market Deep Research Report with Forecast - openPR.com
HPV16+ Anogenital Cancers Therapeutics Market Size in 7MM - openPR.com
ADAR1 Capital Management LLC Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Massachusetts Financial Services Co. MA Cuts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Is Vertex Pharmaceuticals Stock a Buy? - The Motley Fool
Learn to Evaluate (REGN) using the Charts - news.stocktradersdaily.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Decreased by Fmr LLC - MarketBeat
Russell Investments Group Ltd. Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Ilmarinen Mutual Pension Insurance Co Has $8.12 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Resona Asset Management Co. Ltd. Invests $26.51 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Bryce Point Capital LLC Invests $558,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Wellington Management Group LLP Sells 291,780 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Orion Portfolio Solutions LLC - MarketBeat
Leerink Partnrs Issues Pessimistic Outlook for REGN Earnings - MarketBeat
Atlas Capital Advisors Inc. Boosts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Blair William & Co. IL Sells 788 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Venous Thromboembolism Market Anticipated to Expand Rapidly - openPR.com
Jefferies Adjusts Regeneron Pharmaceuticals' Price Target to $936 rom $1,120, Keeps Buy Rating - MarketScreener
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Rhenman & Partners Asset Management AB - MarketBeat
Grantham Mayo Van Otterloo & Co. LLC Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Middle East And Asia Pacific Cell And Gene Therapy Market - openPR.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Short Interest Up 26.5% in March - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by O Shaughnessy Asset Management LLC - MarketBeat
Geode Capital Management LLC Buys 155,369 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Kesler Norman & Wride LLC Acquires Shares of 443 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Pamalican Asset Management Ltd Purchases New Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Orion Investment Co Has $21.29 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron: Market Overlooks A Resilient Franchise And Robust Free Cash Flow - Seeking Alpha
Regeneron Pharmaceuticals - drugdiscoverytrends.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Trexquant Investment LP - MarketBeat
Regeneron Pharmaceuticals (NasdaqGS:REGN) Drops 10% Over Last Week Despite Dupixent Approval in Japan - simplywall.st
Schroder Investment Management Group Sells 13,477 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
CIBC Private Wealth Group LLC Decreases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by AIA Group Ltd - MarketBeat
Mammalian Cell Fermentation Technology Market Top Players - openPR.com
JPMorgan Chase & Co. Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
California Public Employees Retirement System Decreases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Increased by RWA Wealth Partners LLC - MarketBeat
Franklin Resources Inc. Acquires 149,124 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Leerink Partnrs Has Pessimistic Outlook of REGN Q1 Earnings - Defense World
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Cannell & Spears LLC - MarketBeat
WINTON GROUP Ltd Sells 755 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
May 23rd Options Now Available For Regeneron Pharmaceuticals (REGN) - Nasdaq
Bernstein Adjusts PT on Regeneron Pharmaceuticals to $979 From $1,010, Maintains Outperform Rating - MarketScreener
Bernstein cuts Regeneron stock price target to $979, maintains Outperform By Investing.com - Investing.com UK
Allstate Corp Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Pictet Asset Management Holding SA - MarketBeat
DnB Asset Management AS Acquires 2,685 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Regeneron Pharmaceuticals Inc Stock (REGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McCourt Marion | EVP Commercial |
Nov 01 '24 |
Option Exercise |
381.40 |
1,000 |
381,400 |
13,931 |
| McCourt Marion | EVP Commercial |
Nov 01 '24 |
Sale |
844.61 |
1,000 |
844,610 |
12,931 |
0.62%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):